






18th World Vaccine Congress Agenda: Day 1 – Tuesday 10th October 2017




Plenary Session ROOM: RUBI/ZAFIR			
08:50	Chair's opening remarks Dr Gregory Poland, Director, Mayo Clinic		
09:00	Opening plenary discussion: Creating a new strategy - How does the current global outbreak response system need to change? Moderator: Dr Gregory Poland, Director, Mayo Clinic Speakers: Dr Marie-Paule Kieny, Former Assistant Director-General - Health Systems and Innovation, WHO Richard Hatchett, CEO, CEPI Prof Helen Rees, Chair and Executive Director, Wits Reproductive Health and HIV Institute		
10:00	Maternal immunisation: Where do we stand and how do we use vaccines, antivirals and antibodies – What's the strategy? Francesca Ceddia, VP, Head Global Medical Affairs Vaccines, GSK Vaccines		
10:30	<i>Break the ice with your peers and exchange business cards in the conference room</i>		
10:40	Morning Networking Break		
	 ROOM: RUBI	 ROOM: ZAFIR	 ROOM: ROSSINI
11:40	Chair's opening remarks Dr Emmett V. Schmidt, Exec Director, Clinical Research, Merck Research Laboratories - Oncology	Chair's opening remarks Dr Gregory Poland, Director, Mayo Clinic	Chair's opening remarks Nathalie Garcon, CEO/CSO, BIOASTER
	Therapeutic & Immunotherapy Vaccines	Influenza Vaccines	Discovery and Drivers for Emerging Diseases
11:45	Why haven't Alzheimer's vaccines succeeded yet? Professor Nikolai Petrovsky, Flinders University School of Medicine & Chairman of Vaxine Pty	Clinical development of a nasal inactivated influenza vaccine Dr Anna-Karin Maltais, CSO, Eurocine Vaccines	Bringing together experts in human and animal health to create new platforms and technologies that will facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge Dr Jean-Christophe Audonnet, Senior Director, Research Strategy and Key Alliances, Bio R&D, Merial and Coordinator, ZAPI Dr Bart Haagmans, Working Group Leader, Department of Viroscience, Erasmus M.C., & Co-coordinator, ZAPI
12:15	Delivering precision immunotherapy - Reprogramming dendritic cells to target patient specific antigens Jeff Abbey, CEO, Argos Therapeutics	Progress and potential hurdles for development of a universal flu vaccine Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines	

12:45	Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity Dr Peter Timmerman, CSO, Pepscan Therapeutics	The challenge of childhood influenza vaccination in Europe Dr Ruprecht Schmidt-Ott, European Director for Scientific Affairs & Public Health, GSK Vaccines	Virus discovery – New kids on the block with pandemic potential Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover
13:15	Networking Lunch & Poster Session		
14:45	A pan-HLA predictor of antigen processing and presentation to the cell surface improves the identification of clinically relevant neoantigens Dr Trevor Clancy, Co-Founder and Chief Scientific Officer, Oncolmmunity	Assays used for vaccine efficacy studies and correlates of protection for influenza vaccines evaluation Prof Emanuele Montomoli, Professor at the Public Health University of Siena & CSO, VisMederi	Innovative mRNA vaccines – From proof of concept to product development, Rabies as an example Dr Susanne Rauch, Senior Scientist, CureVac
15:00		Mucosal and systemic immune responses to influenza following oral tablet delivery Dr Sean Tucker, CSO, Vaxart	
15:15	Using DNA vaccine based technology to prevent potentially life threatening allergies Salim Mujais, SVP, Therapeutic Area Head Immunology, Transplant, Infectious Disease, CNS and Pain, Astellas Pharma	RSV Vaccines Prepare Trial: A global, multi-season, Ph 3 trial to evaluate the protective efficacy of the RSV F nanoparticle vaccine in infants using maternal immunization Dr Gregory Glenn MD, President, Research and Development, Novavax	Use of vaccination in animals for total epizootic disease eradication and anti-microbial resistance control Dr Joseph Domenech, Consultant, ex World Animal Health Organization (OIE) Chargé de Mission and FAO Head of Animal Head Service
15:45	Data supporting the value of check point inhibitors, AMPLIVANT SLP conjugates and neoantigens in combinational immunotherapy against HPV cancers Willem-Jan Krebber, COO, ISA pharmaceuticals	Update on the development of the recombinant RSV vaccine candidate MVA-BN® RSV Dr Nathaly Samy, Senior Vice President Clinical Development, Bavarian Nordic	Nanovaccines: A new platform technology for immunization against avian infections that impact human health Dr Adel M. Talaat, Prof of Microbiology, University of Wisconsin-Madison

16:15	Afternoon Networking Break		
16:45	<p>The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics</p> <p>Dr Angus Dagleish, Foundation Chair in Clinical Oncology & Research Director, St George's University, London</p>	<p>Landscape analysis of RSV vaccine development and future implications</p> <p>Dr Marta Nunes, Respiratory and Meningeal Pathogens Research Unit, University of Witwatersrand, Soweto South Africa</p>	<p>New insight and the challenges associated with the prevention and control of Rift Valley fever</p> <p>Dr Osama Ahmed Hassan Ahmed, Epidemiologist, Center for Global Health, Department of Community Medicine and Global Health, Oslo University</p>
17:15	<p>Oncolytic viruses as immunotherapy - Establishing the legitimacy of oncolytic viruses in cancer therapy</p> <p>Dr Brian R. Champion, CSO, PsiOxus Therapeutics</p>	<p>Developments and updates on an adjuvanted RSV F RSV Vaccine to protect healthy and high-risk older adults: Building on clinical experience</p> <p>Dr Vivek Shinde, MD, MPH, Director, Clinical Development, Novavax</p>	<p>Development of proprietary polysaccharide vaccine adjuvants that meet the needs of humans and animals when concerning Influenza, West Nile and other re-emerged viruses</p> <p>Professor Nikolai Petrovsky, Flinders University School of Medicine & Chairman of Vaxine Pty</p>
17:45	<p>Chair closing remarks of day one followed by Drinks Reception @ Fabrica Mortiz Barcelona – Coaches leave from 6pm for a 5 min drive</p> <p>Hosted by:</p> <div style="display: flex; justify-content: center; align-items: center; gap: 20px;">   </div>		

Day 2 – Wednesday 11th October 2017

	 ROOM: RUBI/ ZAFIR	 ROOM: ROSSINI	 ROOM: DIAMANT
09:00	Chair's opening remarks Dr Gregory Poland, Director, Mayo Clinic	Chair's opening remarks Nathalie Garcon, CEO/CSO, BIOASTER	Chair's opening remarks Prof Farzin Farzaneh, Professor of Molecular Medicine, King's College London & Honorary Consultant in Specialist Medicine, King's College Hospital NHS Trust
09:10	Plenary discussion: Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia Dr Suresh Beri, Additional Director, Conjugate Vaccines, Serum Institute of India Dr Krishna Ella, Founder and Chairman, Bharat Biotech Dr Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP)	Control, Prevention & Breakthrough Trends Changing Veterinary Vaccine Landscapes	Exciting Immune-Manipulation Approaches
		Prevention of food borne diseases through vaccination: Challenges and opportunities in the global poultry industry Dr Dharanesh Gangaiah, Bacteriologist, Molecular Bacteriology and Bacterial Foodborne Illnesses, Elanco	Development of TCR based adoptive T cell therapies: opportunities and challenges Dr Kai Pinkernell, Chief Medical Officer and Senior Vice President of Medical Affairs, Medigene
09:40	Dr Jean Lang, Associate Vice President, R&D, NV Projects Global Health, Partnerships & Funding, Sanofi Pasteur Yves Leurquin, Head, Vaccines Market Access, Takeda Pharmaceuticals International	Disease prevention in relation to animal welfare Rik Koopman, Global Technical Director, MSD Animal Health	Combinational immunotherapy in oncology: Increasing the effective targeting of neo-epitopes Dr Emmett V. Schmidt MD PhD, Executive Director, Clinical Research, Merck Research Laboratories - Oncology
		Bioprocessing, Manufacturing and Innovative New Technology	
10:10	Where are we in polio eradication? What are the remaining challenges? Dr Phil Minor, Former Deputy Director, Head of Virology, NIBSC & Member of the WHO Advisory Panel on Biological Standardization	Development of a serum free medium for expansion of BHK-21 cells for vaccine production Dr James W. Brooks, R&D Manager, BD Biosciences	Integrated immune monitoring solutions for preclinical and clinical development of immunotherapeutics Dr Marcelle Van Mechelen, Senior Scientific Advisor, Caprion Biosciences Inc.
10:40	Morning Networking Break		

11:40 - 13:10	  <p>2 x Interactive Roundtables: 11:40 to 12:25 (rotation one) and 12:25 to 13:10 (rotation two). If you have not filled out the survey please choose them on the sign-up sheets located outside of the exhibition hall/or ask registration for more information. Choose two x 45 min long roundtables for these interactive discussions with like-minded peers in:</p>				 <p>ROOM: DIAMANT</p>
ROOM: RUBI	<p>1. Incorporating “passive immunization” with vaccines – the use of Phage therapies and mABs Dr Eszter Nagy, Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH</p>	<p>2. The significant role of the microbiome in disease prevention, treatment and therapeutic development Jeff Riley, Synthetic Biologics, Inc.</p>	<p>3. Progress on Zika vaccine development Dr Gregory Poland, Director, Mayo Clinic</p>	<p>11:40 Advanced development of innovative immunotherapeutics: In combination and exploiting the DART platform Dr Paul Moore, Vice President-Immunology & Cell Biology, MacroGenics</p>	
	ROOM: ZAFIR	<p>4. Intradermal delivery of therapeutic vaccines – benefits and challenges Dr Kirsty V Gapp, Global Business Manager Transdermal and Microneedle Drug Delivery, 3M</p>	<p>5. The regulators relationship with Challenge Studies; yesterday, today & tomorrow Bruno Speder, Head Clinical Regulatory Affairs, SGS Life Sciences Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences</p>	<p>6. Trends in mammalian cell culture based vaccines Ron Geven, EU Key Account Manager, BD Biosciences Dr James W. Brooks, R&D Manager, BD Biosciences</p>	<p>7. Sponsor/CRO Partnership Optimization Marc Hoffman, CMO, Celerion Bernhard Liegl, VP Global Clinical Development, Celerion Susanne Eder-Lingelbach, Head of Clinical Operations, Valneva</p>
ROOM: ROSSINI		<p>8. Advanced veterinary therapies: stem cells, monoclonal antibodies and bacterial phages for veterinary use Dr Rosario Bullido, Head of Veterinary Immunological Medicines Assessment Unit, AEMPS</p>	<p>9. Developing vaccines to emerging diseases and effective use of animal models Professor Miles W Carroll, Head of Research, Deputy Director, National Infections Service, Public Health England</p>	<p>10. Porcine T lymphocytes – analysis of their response after vaccination Prof Dr Armin Saalmüller, Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine Vienna</p>	<p>11. Using an autologous cancer vaccine to enhance immunotherapy outcomes and tackle a re-occurring disease within companion animals Dr Patrick Frayssinet, R&D Director, URODELIA</p>
	13:10	Networking Lunch & Poster Session			






	Emerging & Re-emerging Diseases ROOM: RUBI	Clinical Development in Viral Vaccines ROOM: ZAFIR	Early Development & Manufacturing ROOM: VIVALDI	ROOM: ROSSINI	ROOM: DIAMANT
14:40	Chair's opening remarks Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover	Chair's opening remarks Professor Miles W Carroll, Head of Research, Deputy Director, National Infections Service, Public Health England	Chair's opening remarks Dr Antu Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative (IAVI)	Chair's opening remarks Glen Gifford, Chargé de mission, Science and New Technologies Department, OiE	Improving the anti-tumor immune response through the use of bi-and trifunctional antibody-cytokine fusion proteins Dr Dafne Mueller, Group Leader, Institute of Cell Biology and Immunology, University of Stuttgart
	Biopreparedness and Vaccine Progression	Clinical Outcomes in Viral Vaccines	New Platforms and Process Development	Emerging and Re-emerging Diseases	
14:45	Development of live measles vaccine vector for new emerging pathogens Dr Frédéric Tangy, Director of R&D, CNRS, Institut Pasteur	The challenges of clinical development for emerging infectious diseases – The example of Ebola Dr Melanie Saville, VP, Head of Late Development, Clinical and Medical Affairs, Janssen	Pre- formulation and stability studies in different vaccines – key considerations Dr Florence Arvis, Head of Formulation Unit, Sanofi	Manufacturing within the veterinary industry – the future of where it's going Randolph Seidler, Managing Director, Veterinary Research Centre & VP, Global Head of BD, Boehringer Ingelheim	Accuracy and prediction in antibody repertoire analysis Dr Sai Reddy, Assistant Professor, Department of Biosystems Science & Engineering, Laboratory for Systems and Synthetic Immunology, ETH Zurich / Swiss Federal Institute of Technology
15:10					
15:15	Strain and species-specific antibody response in a malaria vaccine field trial and after flavivirus infection Dr John Tan, Senior Scientist, Technology Innovation, Roche Sequencing Solutions	The problem with powering...PhII to PhIII, quo vadis? Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences	How innovative process development allows for a novel cost-effective rotavirus vaccine Dr Alfred Luitjens, Director Cell Technology, Batavia Biosciences	Prioritising diseases for which vaccines could reduce antimicrobial use in animals preserving the effectiveness of antibiotics Dr Glen Gifford, Chargé de mission, Science and New Technologies Department, OiE	
15:30			Innovative affinity chromatography platform for streamlined purification of vaccines at reduced costs and lower environmental footprint Anne Chevrel, Research and Development Project Manager, Affilologic		
15:45	Afternoon Networking Break				

16:15	Developing a universal vaccine against emerging mosquito-transmitted diseases and influenza Dr Olga Pleguezuelos, CSO & Project Manager, SEEK	Use of MAV-VLP platform for development of vaccines for infectious diseases and cancer Dr Farshad Guirakhoo, CSO, GeoVax, inc.	Bioengineering bacterial outer membrane vesicles as vaccine platform Dr Ivo Ploemen, Program Manager, Intravacc	The role of omics in veterinary vaccinology: Opportunities and challenges Dr Artur Summerfield, Professor for Veterinary Immunology, Group Head, Institute of Virology and Immunology	Adjuvant profiling and systems analysis of vaccine induced response to enhance correlates of protection of human vaccines Dr Ali Harandi, Associate Professor, Lab head, University of Gothenburg
16:30			MACIVIVA – Developing cold chain independent virosomal vaccines Dr Sylvain Fleury, CSO, Mymetics		
16:45	From vaccines research to launch of Dengvaxia and collaborative efforts to create a Zika vaccine Dr Jean Lang, Associate Vice President, R&D, NV Projects Global Health, Partnerships & Funding, Sanofi Pasteur	ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology Dr Carel van Baalen, Director R&D, Viroclinics Biosciences	Challenges of RSV vaccine development Rob Dekker, CMC Team Lead, Janssen Infectious Diseases and Vaccines	African Swine Fever - Dealing with what is yet to come Dr Marisa Arias, Technical Director, EU Reference Laboratory for African swine fever, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA-CISA)	Oncolytic Virotherapy: A New Cornerstone for Immuno-Oncology Dr Shruthi Naik PhD, Founder and VP, Comparative Oncology, Vyriad & Department of Molecular Medicine, Mayo Clinic
17:00			Interactive panel: Accelerated development of vaccine products to human clinical trials – Successes and challenges Dr Antu Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative (IAVI) Dr Kunal Aggarwal, Head of Technical R&D Programs - R&D Center USA, GSK Vaccines Dr Anissa Boumlic-Courtade, Associate Director, Vaccine initiative, Merck Life Sciences Dr Melanie Saville, VP, Head of Late Development, Clinical and Medical Affairs, Janssen	Q&As with speakers and summary followed up by chair closing remarks for Day 2	Q&As with speakers and summary followed up by chair closing remarks for Day 2
17.15	Preventing the pandemic potential of MERS-CoV: Updates on research and clinical development Dr James Cummings, VP, Clinical Development and Translational Medicine, Novavax	Standardization and development of assays for assessment of influenza vaccines correlates of protection Patricia Londono-Hayes, Head R&D Initiatives Europe, Sanofi			
17:45	Chair's closing remarks followed by Meet & Greet with key speakers in the Exhibition Hall				

				 ROOM: ROSSINI	 ROOM: DIAMANT	
		New Technology & Discovery ROOM: RUBI	Bacterial Vaccines & Anti-Microbial Resistance ROOM: ZAFIR	Technology Supporting Delivery & Manufacture ROOM: VIVALDI	Emerging and Re-emerging Diseases	Immune Response and Biomarkers: B-cell & T-cell analysis
09:00	Chair's opening remarks Dr Jeffrey Almond, Former Vice President Discovery Research and Development, Sanofi and Visiting Professor, University of Oxford	Chair's opening remarks Dr Jan T Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen	Chair's opening remarks Dr Antu Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative (IAVI)	Chair's opening remarks Dr Glen Gifford, Chargé de mission, Science and New Technologies Department, OIE	Chair's opening remarks Dr Sai Reddy, Assis Prof, Dpt of Biosystems Science & Engineering, Lab for Systems and Synthetic Immunology, ETH Zurich/Swiss Federal Institute of Technology	
	New Technology Showcases	Tuberculosis Symposium	Delivery & Manufacture			
09:10	Technology Showcase 1 Proprietary VLP technology for developing safe and efficacious vaccines against enteroviruses and HFMD Dr Zarifah Reed, Medical Director, Sentinext Therapeutics	The role of vaccines to combat antibiotic-resistant bacteria – WHO perspective Dr Martin Friede, Group Lead, Transfer of Technology for Health Products, WHO	Manufacturing capacity planning for live virus vaccines and its impact on product development priorities Dr Scott Shoemaker, Senior Director, Technical operations, Takeda's Global Vaccine Technology and Engineering group	Developing veterinary vaccines for emerging and re-emerging diseases: Gaps and requirements Dr Catherine Charreyre, Head of Research Projects, Merial	Immune correlates and biomarkers of HIV control after therapeutic HIV vaccination and treatment interruption Dr Christian Brander, CSO Aelix Therapeutics, ICREA Research Professor, IrsiCaixa A.I.D.S. Research Institute	
09:25	Technology Showcase 2 Development of a novel vaccine for Zika that does not bear the inherent risk of inducing ADE Dr Farshad Guirakhoo, CSO, GeoVax, inc.					

09:40	Technology Showcase 3 Using mAbs for targeted immunotherapy against bacterial infections Dr Eszter Nagy, Co-Founder, Chief Scientific Officer, and Managing Director, Arsanis Biosciences GmbH	VPM1002: A recombinant BCG as a novel infant and post-exposure adult tuberculosis vaccine Dr Bernd Eisele, CEO, Vakzine Projekt Management GmbH	Virus safety for viral vaccines and viral vectors Dr Anissa Boumlic-Courtade, Associate Director, Vaccine initiative, Merck Life Sciences	A transboundary problem: Lumpy Skin Disease (LSD) Prof Thierry van den Berg, Head of the Department on Animal Infectious Diseases, CODA-CERVA (Veterinary and Agrochemical Research Centre)	Immune profiling of anti-drug antibodies Dr Yariv Wine, Senior Lecturer, Tel Aviv University
09:55	Technology Showcase 4 Structure-based design to tackle vaccine challenges Hans (JPM) Langedijk, Director Subunit Vaccine Design, Janssen Infectious Diseases and Vaccines				
10:10	Technology Showcase 5 The next generation of conjugate vaccine against Streptococcus pneumoniae infection: A novel bioconjugation approach Dr Amir Faridmoayer, Co-Founder & Vice President Discovery, LimmaTech Biologics	Prevention of relapse after Abx treatment Dr Steve Reed, Founder, President and CEO, IDRI	Viral vectors as vaccine platforms: From immunogenicity to impact Dr Katie Ewer, Senior Immunologist, Supervisor, Jenner Institute, Oxford University	Peste des Petits Ruminants: State of affairs and the road towards eradication Dr Arnaud Bataille, Researcher in Virology, CIRAD, Deputy Head of OIE/FAO Reference Laboratory for PPR & Deputy Head of EU Reference Laboratory for PPR	Developing effective biomarker strategies for advanced clinical development of Immune mobilising monoclonal TCRs against cancer (ImmTACs) Dr David Krige, Head of Biomarkers, Immunocore Limited
10:25	Technology Showcase 6 Novel eVLP candidates to prevent leading causes of congenital birth defects Adam Buckley Vice President, Business Development, VBI Vaccines				
10:40	Morning Networking Break				

11:20	Technology Showcase 7 Producing affordable vaccines with high productivity manufacturing technologies Dr Renaud Jacquemart, Director Vaccines Process Sciences, Natrix Separations, now part of MilliporeSigma	Bacterial Vaccines in Clinical Development Extraintestinal pathogenic E. coli: Challenges for vaccine development and clinical progress Dr Jan T Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen	Advances in intradermal drug delivery Dr Yotam Levin, CEO, NanoPass Technologies Henrik Hornsved, Senior Business Development Manager, West Pharmaceutical Services	Application of DIVA vaccines to address Bovine Tuberculosis in Cattle Martin Vordermeier, Team Leader, Animal Health and Veterinary Laboratories Agency	Harnessing natural bacterial products to develop pioneering and gentle immunotherapy treatments Dr Laura Rosa Brunet, Former Chief Scientific Officer, Immodulon Therapeutics Ltd & Director, Rosa Brunet Consulting Ltd
11:40	Technology Showcase 8 Displaying antigens on Virus-Like-Particles using the plug-and-display SpyCatcher/SpyTag technology Prof Sumi Biswas, Associate Professor, University of Oxford	Clinical update on the Staphylococcus aureus multi-antigen vaccine Dr Stephen Lockhart, Vice President and Head of Europe and Asia-Pacific Vaccine Clinical Research and Development (VCRD), Pfizer	Overview of the challenges and opportunities presented by plant-based vaccine manufacturing Dr Vidadi Yusibov, Executive Director, Fraunhofer USA	The Global Virome Project: Bringing an end to pandemics Dr Peter Daszak, President, EcoHealth Alliance	Immuno-oncology, Chronic & Autoimmune Disease Approaches
11:50	Technology Showcase 9 From Chikungunya to Zika and other emerging diseases: rapid development based on vector platform Alexander Kort, Head of Business Processes & Quality, Themis Bioscience	The threat GAS as AMR rises and the promise of a vaccine Prof David Goldblatt, Professor of Vaccinology and Immunology, UCL			ABX196, a promising iNKT agonist to enhance therapeutic efficacy in oncology Dr Sandrine Crabe, Director R&D, ABIVAX
12:20	Afternoon Networking Lunch				

 ROOM: RUBI/ZAFIR		 ROOM: ROSSINI		 ROOM: DIAMANT	
13:20	Chair's opening remarks Dr Gregory Poland, Director, Mayo Clinic	13:20	The quest to develop new and improved vaccines for a range of economically important livestock diseases Dr Richard Mole, Commercialisation Manager, Moredun Research Institute	13:20	Engineering 2nd Generation SPEAR™-T cells to Overcome TGF-β-Mediated Immunosuppression Dr Rachel Abbott, Group Leader, Adaptimmune
13:30	Vaccines against antibiotic resistance: The PCV paradigm Prof Ron Dagan, Professor of Paediatrics and Infectious Diseases, Paediatric Infectious Disease Unit, Soroka University Medical Center	Regulation & Funding			
13:50		13:50	Interactive Discussion: Fast track licensing - Rapid registration of novel vaccine platforms panel Dr Rosario Bullido, Head of Veterinary Immunological Medicines Assessment Unit Veterinary Medicines Department, AEMPS Philippe Migraine, Director Regulatory Affairs, Biologicals New Projects, Meril Jean de Foucald, Senior Bio Regulatory Expert, Ceva	13:50	Targeting cancer neoantigens: A promising source of immunogens for cancer immunotherapy Philip Arlen, President and Chief Executive Officer, Precision Biologics Inc
14:05	The intestinal microbiome and vaccine effectiveness: Correlation or causality Dr Vanessa Harris, Amsterdam Institute for Global Health and Development, University of Amsterdam	14:20		14:20	Enabling boosted anti-tumor immunity by use of an immuno-oncology-dedicated adenosine receptor antagonist Dr Reece Marillier, Research Scientist, in vivo Pharmacology Lead, iTeos Therapeutics SA
14:50		14:50	Increasing availability of veterinary medicinal products through harmonisation of national regulation regarding autogeneus farm specific vaccines Jean de Foucald, Senior Bio Regulatory Expert, Ceva	14:50	Immunoprofiling of tumour-draining lymph nodes: new targets for early intervention Dr Tanja De Gruijl, Professor of Translational Tumor Immunology, V.U. Medisch Centrum
14:55	Plenary Discussion: Vaccines don't protect, vaccination does! Moderator: Dr Gregory Poland, Director, Mayo Clinic Speakers: Dr Bart Haagmans, Working Group Leader, Department of Viroscience, Erasmus M.C., & Co-coordinator, ZAPI Dr Norman Begg, Vice President, Head of Scientific Affairs and Public Health, GSK Vaccines Prof Susanna Esposito, Professor & Chairperson of ESCMID, University of Perugia, Italy	15:20	Harmonisation of registration requirements for veterinary vaccines in East Africa and a regional, time-based mutual recognition procedure Gillian Cowan, Regulatory Affairs Consultant	Speaker Q&As and chair closing remarks	
15:40 Chair's closing remarks and close of Congress		15:50 Chair's closing remarks and close of Congress		15:40 Chair's closing remarks and close of Congress	